Abstract 26P
Background
Gasotransmitters have been established as key players in cancer pathophysiology including breast cancer (BC). Hydrogen sulfide (H2S), being the newest member of gasotransmitters family, was found to be highly elevated in BC tissues. Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) are the endogenous producers of H2S in viable cells. High expression of CBS and CSE in BC tissues was noticed. However, 3MST received less attention. Thus, the aim of this work is to unravel the expression pattern and regulation of 3MST in BC patients and cell lines.
Methods
BC female patients (n=20) were recruited. Patients’ clinical features showed that 65% of patients had lymph node metastasis, 15% were in stage 3-4 of BC, 25% had tumor size ≥5 cm, and 45% were in premenopausal status. Total RNA was extracted using Biazol, reverse transcribed and quantified using qRT-PCR. Western blot analysis was used to quantify the protein. In-silico analysis was used to identify microRNAs (miRNAs) targeting 3MST. MDA-MB-231 cells were cultured and transfected using oligonucleotides. H2S levels were measured by fluorescence probe (AzMc). Functional analysis experiments such as trans-well migration, MTT and colony forming assays were performed in MDA-MB-231 cells following ectopic miR-548 expression.
Results
3MST was found to be significantly up-regulated in BC tissues compared to the non-cancerous tissues. Significant high expression for 3MST was correlated to tumor size ≥5 cm, albeit not to lymph node metastasis nor to menopause. MiR-548 was listed among the top potential regulators of 3MST using 6 different bioinformatics softwares. Ectopic expression of miR-548 in MDA-MB-231 cells resulted in a marked repression of 3MST on both mRNA and protein levels. H2S levels were significantly repressed by 3MST siRNAs and miR-548 mimics. On the functional level, miR-548 markedly reduced cellular viability, migration and colony forming ability of MDA-MB-231 cells.
Conclusions
This study sheds light onto the significant involvement of 3MST in H2S signaling and its positive correlation with BC aggressiveness. Moreover, it highlights its potential target-ability using miR-548 as a novel tumor suppressor therapeutic approach in BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swiss National Science Foundation (SNSF), grant SNF IZSTZ0_198887.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
13P - Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates
Presenter: Anna-Maria Georgoudaki
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - Lentivirally overexpressed c-Myc promoter binding protein (MBP-1) localizes in the cytoplasm of human cutaneous melanoma cell lines increasing cell proliferation and glycolysis rate
Presenter: Miriam Hippner-Kunicka
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments
Presenter: Mario Kuttke
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells
Presenter: Luiz Gustavo Chuffa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
Presenter: Marina Rodriguez-Candela Mateos
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
Presenter: Vlada Zakharova
Session: Cocktail & Poster Display session
Resources:
Abstract
20P - Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Presenter: Pranshu Sahgal
Session: Cocktail & Poster Display session
Resources:
Abstract
21P - Cross-resistance between platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi) in castration-resistant prostate cancer (CRPC)
Presenter: Peter Slootbeek
Session: Cocktail & Poster Display session
Resources:
Abstract
22P - Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage
Presenter: Wafaa Ramadan
Session: Cocktail & Poster Display session
Resources:
Abstract
23P - Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer
Presenter: Deniz Gulfem Ozturk
Session: Cocktail & Poster Display session
Resources:
Abstract